受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | SCH 417690 (SCH-D) Malate | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C28H38F3N5O2.C4H6O5 |
|||
分子量 | 667.72 | CAS No. | 541503-81-5 | |
Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (149.76 mM) | |
Water | 100 mg/mL (149.76 mM) | |||
Ethanol | 100 mg/mL (149.76 mM) | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Vicriviroc is a potent CCR5 antagonist with IC50 of 0.91 nM, showing broad-spectrum activity against genetically diverse HIV-1 isolates, and also drug-resistant viruses with RTI, PRI, or MDR phenotypes. Phase 3. |
---|---|
in vitro | Vicriviroc binds with higher affinity to CCR5 versus SCH-C (SCH-351125) in competition binding assays with Ki value of 0.8 nM versus 2.6 nM. Vicriviroc is nearly 6-fold less active than SCH-C (IC50 = 5.8 μM versus 1.1 μM) in attenuating hERG current among voltage-clamped L929 cells, indicating a reduced potential for cardiac effects. Vicriviroc inhibits MIP-1α induced migration of Ba/F3 cells stably expressing recombinant human CCR5, with IC50 of 0.91 nM. In U-87-CCR5 cells, Vicriviroc inhibits intracellular calcium release induced by the ligand RANTES with IC50 of 16 nM, while Vicriviroc treatment alone does not stimulate the release of calcium. Vicriviroc inhibits GTPγS binding to the membranes from HTS-hCCR5 cells induced by RANTES, with IC50 of 4.2 nM. Vicriviroc displays potent antiviral activity against a panel of 30 R5-tropic HIV-1 isolates representing diverse genetic clades, with EC50 values ranging from 0.04 nM to 2.3 nM, and EC90 from 0.45 nM to 18 nM, being more potent (2- to 40-fold) than SCH-C. Vicriviroc is also highly active against a Clade G Russian isolate RU570 with EC90 of 16 nM, which is resistant to inhibition by SCH-C (EC90 > 1 μM). Vicriviroc could target an early step in the viral life cycle prior to reverse transcription and virion maturation, the targets of reverse transcriptase inhibitor and protease inhibitor, respectively. Consistent with the selectivity for CCR5, Vicriviroc is not active against viruses capable of using the CXCR4 coreceptor (R5/X4 or X4 tropic) for infection. [1] |
キナーゼアッセイ | Chemotaxis assay | |
---|---|---|
Ba/F3-CCR5 cells in chemotaxis buffer (RPMI supplemented with 1% FBS and 0.1 μg/mL mouse IL-3) are pretreated for 1 hour with increasing concentrations of Vicriviroc at 37 °C. Chemotaxis buffer containing Vicriviroc and MIP-1α (0.3 nM), MIP-1β (0.3 nM), or RANTES (0.3 nM) is placed into the bottom well of a 5-μm ChemoTx plate, and the filter unit is placed over the wells. Ba/F3-CCR5 cells pretreated with Vicriviroc are pipetted (25 μL) onto the filters, and the plate is incubated at 37 °C for 2 hours. Unmigrated cells are scraped off the filter, and the plate is centrifuged to pellet-migrated cells. Cells are then transferred to a Microlite 1+ Flatbottom Microtiter plate and quantitated using the Cell Titer Glow luminescent cell viability assay kit. IC50 value for Vicriviroc is calculated using GraphPad Prism Software. |
Data from [Nature, 2013, 493, 51-5]
Data from [J Antimicrob Chemother, 2011, 66, 802-812]
Data from [J Antimicrob Chemother, 2011, 66, 802-812]
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. [Alonzo F 3rd, et al. Nature, 2013, 493(7430):51-5] | PubMed: 23235831 |
CCR5 antagonist blocks metastasis of basal breast cancer cells. [Velasco-Velázquez M, et al. Cancer Res, 2012, 72(15):3839-50] | PubMed: 22637726 |
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. [Zembruski NC, et al. J Antimicrob Chemot, 2011, 66(4):802-12] | PubMed: 21393174 |
Decreased HIV diversity after allogeneic stem cell transplantation of an HIV-1 infected patient: a case report. [Kamp C, et al. Virol J, 2010, 7:55] | PubMed: 20210988 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。